In agreement with this data, selumetinib shows activity in pediatric patients with NF1-associated low-grade glioma.5,7 However, adverse events are common and some patients progress despite treatment.5,7 This could be due to individual differences in tissue penetration or acquired efflux transporter-mediated resistance in certain patients. This evidence concerns the gene NF1 and glioma.